Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
DHNP-2204
- Development stage
- Preclinical
- Lead developer
- Daehan Nupharm
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
DHNP-2204 is a small molecule therapeutic candidate currently under development by the South Korean pharmaceutical company Daehan Nupharm. Targeted for the treatment of obesity, the drug is presently in the formulation development stage of the company's R&D pipeline. This phase typically involves optimizing the chemical stability, solubility, and delivery profile of the active pharmaceutical ingredient to ensure optimal efficacy and safety before advancing to clinical trials. While the specific biological target and mechanism of action have not been publicly disclosed, DHNP-2204 represents a strategic effort by Daehan Nupharm to expand its portfolio in the metabolic disease and weight management market.
Beyond the preview
Go deeper on DHNP-2204.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on DHNP-2204.